Figures
Abstract
Background
Healthy individuals rarely have problems with wound healing. Most skin lesions heal rapidly and efficiently within one to two weeks. However, many medical and surgical complications can be attributed to deficiencies in wound repair. Open wounds have lost the barrier that protects tissues from bacterial invasion and allows the escape of vital fluids. Without expeditious healing, infections become more frequent. The CD24 gene encodes a heavily-glycosylated cell surface protein anchored to the membrane by phosphatidylinositol. CD24 plays an important role in the adaptive immune response and controls an important genetic checkpoint for homeostasis and autoimmune diseases in both mice and humans. We have previously shown that overexpression of CD24 results in increased proliferation and migration rates.
Methods
An excisional model of wound healing was used and delayed wound healing was studied in genetically modified heat stable antigen (HSA/CD24)-deficient mice (HSA-/-) compared to wild-type (WT) mice.
Results
Large full-thickness skin wounds, excised on the back of mice, exhibited a significant delay in the formation of granulation tissue, and in wound closure when compared to their WTHSA+/+ littermates. Wounds were histologically analyzed and scored, based on the degree of cellular invasion, granulation tissue formation, vascularity, and re-epithelialization. Additionally, in stitched wounds, the HSA-/- mice failed to maintain their stitches; they did not hold and fell already 24 hours, revealing erythematous wound fields. Re-expression of HSA, delivered by lentivirus, restored the normal healing phenotype, within 24 hours post-injury, and even improved the healing in WT, and in BalbC mice.
Citation: Shapira S, Ben-Amotz O, Sher O, Kazanov D, Mashiah J, Kraus S, et al. (2015) Delayed Wound Healing in Heat Stable Antigen (HSA/CD24)-Deficient Mice. PLoS ONE 10(10): e0139787. https://doi.org/10.1371/journal.pone.0139787
Editor: Ajay Goel, Baylor University Medical Center, UNITED STATES
Received: June 16, 2015; Accepted: September 17, 2015; Published: October 6, 2015
Copyright: © 2015 Shapira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper.
Funding: The authors have no support or funding to report.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Most skin lesions heal rapidly and efficiently within one to two weeks [1]. Although being healed, the outcome is neither esthetically nor functionally perfect [2]. In the U.S. alone, 35 million cutaneous wounds require major intervention annually [2].
Normal wound healing is a complex, dynamic and fragile process that is impacted by many factors and is divided into three phases, inflammatory, proliferative and maturation or remodeling [3,4]. After an initial wound, a fibrin clot is formed. In the inflammatory phase, debris and bacteria undergo phagocytosis and removal. Cytokines are released to initiate the proliferative phase. This process manifests with chemotaxis, phagocytosis, angiogenesis, epithelization, collagen degradation and remodeling, production of new glycosaminoglycans and wound contraction. Wound healing is a highly regulated interplay between systematic expressed cell types (i.e., neutrophils, macrophages, fibroblasts, keratinocytes, endothelial cells), extracellular matrix insoluble components and a group of soluble mediators (i.e., growth factors, cytokines, chemokines) [2,3,5].
The healing process begins with an accumulation of neutrophils and monocytes in the damaged tissue to form a first line of defense. Thereafter, macrophages and mast cells emigrate from nearby tissues and the circulation and accumulate in order to initiate the specific immune response. These inflammatory cells are recruited to the wound site by specific chemotactic factors or chemokines [6,7]. Re-epithelialization and granulation tissue formation include migration of cells from the wound edge to fill the wound site. It involves the migration of keratinocytes over the impermanent matrix in order to rebuild a protective layer [8].
Rapid changes in the extracellular matrix (ECM) occur during the healing process. The fibrin clot is replaced by fibronectin and hyaluronan and subsequently by type I and III collagen [1]. The contribution of each component to the wound repair process is difficult to assess due to the complexity of cells involved in the healing.
The CD24 gene encodes a heavily glycosylated cell surface protein anchored to the membrane by phosphatidylinositol6. Human CD24 consists of 31 amino acids with 16 potential O-glycosylation and N-glycosylation sites. Owing to this extensive glycosylation, CD24 has mucin-like characteristics [9]. It plays a crucial role in cell selection and maturation during hematopoiesis and is expressed mainly on premature lymphocytes and certain epithelial and neural cells [10,11]. CD24 can function as an alternative ligand for P-selectin, an adhesion receptor on activated endothelial cells and platelets [12–14].
CD24 has been previously shown to play an important role in the inflammation [15] process. We also showed that overexpression of CD24 increased proliferation, and migration rates in vitro [16–18].
Herein, it is shown that CD24 plays a major role in wound healing, in HSA-/- knockout (KO) mice as well as normal mice. We explored our theory that CD24(HSA) may be involved and contribute to the healing process. We examined whether there is a relationship between the mice genotype, HSA expression, and the healing process and rate. We confirmed our observations by immunohistochemistry (IHC) and collagen staining, and most importantly by re-expression of the HSA gene. We suggest here, for the first time, a new candidate for improving and accelerating the healing process.
Materials and Methods
Animal housing and procedures
Heat stable antigens (HSA) knockout (KO) mice on a C57BL/6J background were kindly provided by Prof. Peter Altevogt (DKFZ Heidelberg, Germany). Wild-type (WT)HSA+/+ mice were purchased from Harlan Laboratories (Rehovot, Israel). All mice were fed with a standard pellet diet and had access to tap water ad libitum. The animals were maintained at a constant temperature (22±2°C) on a 12 h light/dark cycle and all procedures were approved by the Institutional Committee for Animal Welfare at Tel-Aviv Sourasky Medical Center. Before the procedures, mice were anesthetized by intraperitoneal (i.p.) injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal surface of the animal was cleaned, shaved, and sterilized with a betadine solution. Longitudinal incisions, 1.5–4 cm, were made on the back of the mice. The excised wounds were left open, stitched, or dressed with gauze after virus administration. In HSA/mCherry expression experiments, the virus-containing medium or antibodies were applied once post-wounding. Wound healing was examined by macroscopic observations and histological analysis every day after wound excision. At the end of the experiments, the animals were sacrificed with a lethal dose of CO2.
Virus production
Three HIV-based viral vectors (kindly provided by Prof. Eran Bacharach, Tel Aviv University, Israel); pVSV-G (5 μg), pCMV.ΔR8.2 (15 μg) and pHR’CMV-HSA (or pHR’CMV-mCherry, as negative control) (20 μg) were co-transfected to HEK293T helper cells using the standard calcium phosphate transfection method. hours after transfection, virions-containing supernatants were collected, the pH was adjusted with Hepes, filtered and stored at -80°C.
Infection
Before the infection, polybrene was added to the virions-containing supernatant to a final concentration of 8μg/ml. The supernatant was added to NIH-3T3 cells, that were seeded in 6-cm plates the day before (5x105 cells), for 2 hours. Then, 3 ml of fresh medium was added to the plate and after two days the infected cells were analyzed for the expression of the relevant gene.
In vivo, under anesthesia [intraperitoneal injection of ketamine (50 mg/kg) and xylazine (5 mg/kg)], 300 μl of viruses-containing medium were injected into the cells on the wound border or dropped directly into the wounds area of the mice. Wound closure and mice's well-being were monitored on a daily basis.
In vivo targeting of HSA by anti-HSA mAb
Before the procedures, mice were anesthetized [ketamine (50 mg/kg) and xylazine (5 mg/kg)]. Longitudinal incisions, of 2 cm, were made on the back of the mice. Ten mg/kg of Rat anti-mouse M1/69 IgG2b mAb was administrated topically by injection into the cells on the wound border. Wound closure and mice's well-being were monitored every day.
Imaging of mCherry expression in mice
For all imaging, mice were anesthetized using aketamine-xylazine mixture. For imaging of mCherry expression, mCherry-encoded viruses (300 μl of viruses-containing medium) were injected into the cells on the wound border or dropped directly into the wounds area of WT mice immediately after injury. The mCherry expression was monitored 96 hours later using the Maestro in vivo fluorescence imaging of whole small animals' device.
Histology
At days 0, 3 and 14 days post-wounding, the animals were sacrificed with a lethal dose of CO2, autopsied, and their wound beds surrounded by a margin of non-wounded skin were collected. Samples were fixed with 4% paraformaldehyde overnight at room temperature, embedded in paraffin blocks, and sectioned. After deparaffinization and rehydration, the sections were washed and stained with Hematoxylin and Eosin (H&E) or NovaUltraTM Picro-Sirius Red stain for collagen staining. Tissue sections were then washed, mounted, and visualized on an Olympus AH light microscope at 400× magnification.
Protein extraction and immunoblotting
For protein extraction, cells were washed with PBS, scraped and lysed in 1%Triton buffer (100 mM NaCl, 5 mM EDTA, 1% triton, 50 mM Tris-HCl pH 7.5, 50 mM NaF, and a protease inhibitor cocktail (Roche), added just before use. Following 30 min of incubation on ice, lysates were cleared by centrifugation at 14,000 rpm for 10 min, at 4°C. For immunoblotting, protein samples were electrophoresed alongside a molecular weight marker on 10% SDS-Polyacrylamide gel electrophoresis (PAGE) and Western blot analysis was performed as described below.
Western Blot analysis
Proteins resolved by SDS-PAGE were electro-transferred onto the nitrocellulose membrane. The membrane was blocked for at least 1 h with PBST containing 5% skim milk at room temperature (RT) with slow agitation. Proteins were detected using a specific primary antibody (M1.69, generous gift from Prof. Peter Altevogt; DKFZ Heidelberg, Germany) followed by horseradish peroxidase (HRP)-conjugated secondary antibody and enhanced chemiluminescence (ECL) detection using the EZ-ECL reagent as described by the vendor (Biological Industries, Beith HaEmek).
Flow cytometry analysis
Cellular CD24 binding by rat M1.69 was evaluated by flow cytometry (FACS). Approximately 1x106 cells were used in each experiment. After trypsinization, the cells were washed in fluorescence-activated cell sorting (FACS) buffer (10% FBS, 0.01% sodium azide in ice-cold PBS) and fixed with 2% formaldehyde for 15 min at RT. After washing with FACS buffer, 100 μl of 15 μg/ml anti-CD24 were added for 30 min at RT. After washing X3 with FACS buffer, fluorescein isothiocyanate (FITC)–labeled goat anti-rat (1:100) was added for 30 min at RT. Detection of bound antibodies was performed on a FACSCalibur (Becton Dickinson, San Jose, CA) and results were analyzed with the CELLQuest program (Becton Dickinson).
Statistics
Data from the in vivo studies are presented as mean±SD of sets of data as determined for each group of mice. Statistical significant differences between groups and at different time points were determined by Student t-test, P values <0.05 were considered significant.
Wound areas were calculated by using the ImageJ software. Area selection was created and analyses for the areas were automatically done.
Results
Delayed wound healing in HSA KO mice
Several independent experiments with 10-mm oblong full-thickness excision wounds, including the striated muscle layer, on the dorsal skin of WT (HSA+/+) (n = 5) and KO (HSA-/-) (n = 5) mice demonstrated that the absence of HSA hampered the healing of skin wounds (Fig 1). Moreover, the KO mice failed to keep the stitches in the stitched wounds. Healing of KO mice wounds remained incomplete. In the HSA KO mice, scabs were thicker and erythematous wound fields were shown. Similar results were seen with longer excision wounds (n = 6) (Fig 2).
The left picture in each panel represents the HSA+/+ mouse while the right is for the HSA-/-. A. t = 0, time of injury. B. t = 0, the wounds were stitched upon injury. C. t = 24 h. D. t = 24 h, with stitches. E. t = 7 days. F. t = 7 days, with stitches. G. A representative plot of the statistical differences between the groups. Each bar shows the fold change of the wound area compared to t = 0.
The left picture in each panel represents the HSA+/+ mouse while the right is for the HSA-/-. A. t = 0, time of injury. B. t = 24 h. C. t = 72 h. D. t = 7 days. E. A representative plot of the statistical differences between the groups. Each bar shows the fold change of the wound area compared to t = 0.
Histologic scoring [19] was based on the degree of cellular infiltration, granulation tissue formation, and re-epithelialization (Table 1). Wounds of WT mice had higher average histologic scores compared to the KO mice. There was a greater degree of cellular infiltration and capillary ingrowth in the HSA+/+ mice (Fig 3). In addition, the collagen scoring [20] (Table 2) confirmed the IHC staining; the fibers were still separated with complete loss of architecture in the HSA-/- mice 72h after the wound was established (Fig 4).
Tissue sections were stained with Hematoxylin and Eosin (H&E) and visualized on an Olympus AH light microscope at 400× magnification. The left picture in each panel represents the HSA+/+ mice while the right is for the HSA-/-. A- T = 0, time of injury; B- T = 72h; C- T = 2 weeks. D. Table of the scoring results.
Tissue sections were stained with NovaUltraTM Picro-Sirius Red stain and visualized on an Olympus AH light microscope at 400× magnification. The left picture in each panel represents the HSA+/+ mouse while the right is for the HSA-/-. A. t = 0, time of injury, B. t = 72h, C. t = 14 days. The scoring is detailed in Table 2.
Production of HSA-encoding viruses
Three viral-based vectors were used to deliver and express the HSA gene in the wounded tissue. First, the expression of the transgene by the helper cells, in vitro, was confirmed by monitoring the mCherry fluorescence marker (Fig 5A) and Western blot analysis (Fig 5C). Next, the infectivity of the produced virions was tested in vitro on NIH-3T3 cells. Seventy two hours post-infection of NIH-3T3 cells, the expression of the HSA/mCherry proteins was examined and confirmed by fluorescence microscopy (Fig 5B), Western blot (Fig 5C) and FACS analysis (Fig 5D).
HEK 293T cells were co-transfected with the mentioned plasmids and after 48 h the expression of the transgene was evaluated by the mCherry marker (A). The infectivity of the virions, which was produced by the HEK293T helper cells, was tested on NIH-3T3 in vitro by fluorescence microscope (mCherry expression) (B). 72 h after the infection, cell lysates were prepared and 20 μg of total proteins was loaded. HSA was detected with the anti-HSA mAb, M1.69, and then the membrane was reprobed with anti-human tubulin (C). 1x106 infected cells were incubated with 10 μg/ml of M1.69 for 30 minutes at RT. FITC-labeled goat anti-rat antibody was used for the detection of bound antibody. The red curve represents the negative control (secondary antibody alone) and the green curve represents the binding of M1.69 (D).
Re-expression of HSA restored the healing phenotype
Next, we examined whether the expression of HSA in HSA-/- mice restores the WT healing capabilities. Firstly, we verified that the viruses infected the cells in vivo. To that end, in vivo imaging of the wounded tissue in the WT mice 96hoursafter virus injection/dropping confirmed the expression of mCherry and HSA in the wounded tissue (Fig 6).
The viruses were injected or dropped intothe wounded cells immediately after the injury, on t = 0.96 h after injection into the cells on the wound border (A) or dripping(B-C) of the mCherry-encoded viruses (n = 3) onto the wound area, mice were taken to in vivo imaging to detect the mCherry expression in the wounded cells using the Cri Maestro device. This imaging tool enables multiplexed in vivo fluorescence imaging of small animals with high sensitivity.
Then the importance of HSA in the healing process was evaluated by an additional experiment that was performed as described in Table 3. Briefly, mice from each genotype were randomly divided into groups of three mice. Longitudinal incisions of 1.5 cm were made on their back and the HIV-encoding viruses were administrated by injection into the cells on the wound border or by dropping of the viruses into the wounded area. The healing was monitored every day for one week. Re-expression of HSA restores the healing phenotype in the HSA-/- mice while the expression of the control mCherry vector had no effect (Fig 7).
A-The viruses were injected or dropped into the wounded cells on T = 0; B-HSA-/- mice 24 h after mCherry-encoded viruses injection (left panel) or dropping (right panel); C-HSA-/- mice 24 h after HSA encoded viruses injection (left panel) or dropping (right panel); D-HSA+/+ mice 24 h after mCherry-encoded viruses injection (left panel) or dropping (right panel); E-HSA+/+ mice 24 h after mCherry-encoded viruses injection (left panel) or dropping (right panel); F- 7 days after viruses injection; G- A representative plot of the statistical differences, in size of wound area, between the groups.
Overexpression of HSA in WT mice improves wound healing
We further evaluated the ability of HSA to improve the wound healing process in normal HSA+/+WT mice. For this purpose, we enlarged the wound size and the experiment was performed as described in Table 4. Briefly, HSA+/+ mice were randomly divided into groups of four mice. Longitudinal incisions of4-cm were made on their back and the mCherry or HSA-encoding viruses were administrated twice, 0 and 24 hours post-injury, by injection into the cells in the wound border or by dropping of the viruses into the wounded area and the healing rate was monitored. The results (Fig 8) suggest that overexpression of HSA resulted in faster and improved healing even in HSA-expressing mice. Already after 24 hours it was shown that there were differences in the healing rate between mice that were administrated with mCherry and HSA.
A-The wounds were infected with the viruses (right panel) or left un-treated (left panel) on T = 0; B- HSA+/+ mice 24 h after the injury (left panel), 24 h after infection, by dropping, with the mCherry-encoded viruses (middle panel), 24 h after mCherry-encoded viruses injection (right panel); C- HSA+/+ mice 24 h after infection, by dropping (left panel) or injection (right panel), with the HSA-encoded viruses; D- A representative plot of the statistical differences, in size of wound area, between the groups.
In order to confirm the importance of CD24/HSA in the healing process, a complementary experiment was performed. HSA+/+ mice were randomly divided into groups of three mice. Longitudinal incisions of 2 cm were made on their back and the anti-HSA M1/69 mAb (10 mg/kg) was administrated immediately post-injury by injection into the cells in the wound border. The results suggest that antibody-mediated reduction of HSA expression level caused to slower and non-homogenous healing in HSA-expressing mice (Fig 9).
A-The wounds were treated with anti-HSA antibody (right panel) or left un-treated (left and middle panel) on T = 0; B- HSA+/+ (left panel) and HSA-/- (middle panel) mice 48 h after the injury and HSA+/+ mice 48 h after antibody injection (right panel); C- B- HSA+/+ (left panel) and HSA-/- (middle panel) mice 72 h after the injury and HSA+/+ mice 72 h after antibody injection (right panel); D- A representative plot of the statistical differences, in size of wound area, between the groups. Student t-test was calculated in each time point between the tested group and the wt without treatment group.
The improvement of healing by HSA expression does not depend on the mice strain
In order to examine if the above phenotype depends on the mice strain, we compared between Balb/C and C57Bl/6JWTmice. Eight mice from each strain were randomly divided to two groups of four mice. One group of each strain was injected with HSA-encoding viruses, immediately after the injury, while the second group with the control vector. According to our observations, the wound healing was improved regardless of the mice strain as can be demonstrated in Fig 10.
Four groups of four mice were used in this study. Two of them were of C57/Bl while the other two were of Balb/c. The mice in one group from each strain were injected with the HSA-encoded viruses while the other group with the mCherry-encoded viruses. A- HSA+/+ mice 24 h after mCherry-encoded viruses injection; B- HSA+/+ mice 24 h after HSA-encoded viruses injection; C- HSA+/+ mice 48 h after mCherry-encoded viruses (the two pictures on the left) and HSA-encoded viruses injection (the two pictures on the right); D- HSA+/+ mice 6 days after mCherry-encoded viruses (the two pictures on the left) and HSA-encoded viruses injection (the two pictures on the right); E-A representative plot of the statistical differences, in size of wound area, between the groups. Student t-test was calculated in each time point between the HSA treated group and the mCherry treated group.
Discussion
Our study shows that HSA in mice plays an important role in wound healing. Restoration of the protein restores impaired wound healing back to normal. Moreover, forced expression of HSA enhances the healing process.
CD24 expression has long been correlated with pathologies associated with tumor cell migration and invasion [21–23]. The exact function and mechanism of action of CD24 is mostly unknown; however, it is thought to be involved in a variety of processes such as cell proliferation and it also changes the adhesive properties of tumor cells by promoting their adhesion to P-selectin, fibronectin, collagens I and IV, and laminin [22]. Tumors have been previously described as wounds that do not heal. Wound healing and cancer have similar properties of cellular behavior. They are both characterized by increased cell proliferation, survival, invasion and migration (e.g. angiogenesis and metastasis), remodeling of extracellular matrix, new blood vessel formation, and modulation of blood coagulation. The molecular programs in normal wound healing and those in tumor progression and metastasis were found to be similar [24,25], [26]. Data from our laboratory suggest that overexpression of CD24 is associated with increased cell migration in wound healing assays in vitro (Naumov et al., 2014)[27] showed that cells that overexpress CD24 proliferate faster, and increase and cell motility, saturation density, plating efficiency, and growth in soft agar. They also produce larger tumors in nude mice as compared to the parental cells. In addition, We have shown, Shapira et al., JBC 2011, [28]that induced expression of CD24 in a dose- and time-dependent fashion (using the Tet-On system), led to an increased proliferation which was inhibited by mAb to CD24. In vivo, significantly larger tumors were developed in tetracycline-fed mice compared to the control group. Taking all of this together with the data presented here, we suggest that increased expression of CD24 promotes growth pathways and thus accelerates and improves the healing of wounded tissue. HSA-deficient mice have delayed healing. When the wounds were stitched, the stitches did not hold, suggesting that CD24 is required. In most cases, the healing process was not only delayed but it failed to progress through the normal stages of healing, and resulted in an inflamed scar. Most importantly, re-expression of HSA in HSA-deficient mice, by lentiviruses, restores the wound closure rate in WT mice.
Topical administration of anti-HSA antibodies confirms the genotypic observations of the importance of HSA in normal wound healing.
Interestingly, preliminary data emerging from mouse models of bone (tibia fracture model) fracture and tooth extraction strengthen the importance of CD24 in fracture and tooth extraction healing (Arber et al., unpublished data).
Our hypothesis is that CD24 plays a key role in cell proliferation, migration and adhesion of healthy cells to the damaged area to restore normal tissue. Increased expression of the CD24 protein may represent a novel clinical intervention strategy to accelerate the healing of debilitating acute or chronic wounds in patients.
Author Contributions
Conceived and designed the experiments: SS OBA NA JM EG. Performed the experiments: SS OBA. Analyzed the data: SS OS. Contributed reagents/materials/analysis tools: SS OBA DK OS. Wrote the paper: SS. Edited the paper: SK EG. Histology: OS.
References
- 1. Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, et al. (2005) Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 19: 211–221. pmid:15677344
- 2. Tonnesen MG, Feng X, Clark RA (2000) Angiogenesis in wound healing. J Investig Dermatol Symp Proc 5: 40–46. pmid:11147674
- 3. Martin P (1997) Wound healing—aiming for perfect skin regeneration. Science 276: 75–81. pmid:9082989
- 4. Singer AJ, Clark RA (1999) Cutaneous wound healing. N Engl J Med 341: 738–746. pmid:10471461
- 5. Werner S, Grose R (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83: 835–870. pmid:12843410
- 6. Devalaraja RM, Nanney LB, Du J, Qian Q, Yu Y, et al. (2000) Delayed wound healing in CXCR2 knockout mice. J Invest Dermatol 115: 234–244. pmid:10951241
- 7. Martin P, Leibovich SJ (2005) Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 15: 599–607. pmid:16202600
- 8. Jaakkola P, Kontusaari S, Kauppi T, Maata A, Jalkanen M (1998) Wound reepithelialization activates a growth factor-responsive enhancer in migrating keratinocytes. FASEB J 12: 959–969. pmid:9707168
- 9. Kristiansen G, Sammar M, Altevogt P (2004) Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 35: 255–262. pmid:15339045
- 10. Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, et al. (2001) CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 166: 5567–5577. pmid:11313396
- 11. Kadmon G, von Bohlen und Halbach F, Schachner M, Altevogt P (1994) Differential, LFA-1-sensitive effects of antibodies to nectadrin, the heat-stable antigen, on B lymphoblast aggregation and signal transduction. Biochem Biophys Res Commun 198: 1209–1215. pmid:8117278
- 12. Aigner S, Ruppert M, Hubbe M, Sammar M, Sthoeger Z, et al. (1995) Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol 7: 1557–1565. pmid:8562500
- 13. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, et al. (1997) CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 89: 3385–3395. pmid:9129046
- 14. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, et al. (1998) CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 12: 1241–1251. pmid:9737727
- 15. Ahmed MA, Jackson D, Seth R, Robins A, Lobo DN, et al. CD24 is upregulated in inflammatory bowel disease and stimulates cell motility and colony formation. Inflamm Bowel Dis 16: 795–803. pmid:19998456
- 16. Shapira S, Kazanov D, Weisblatt S, Starr A, Arber N, et al. The CD24 protein inducible expression system is an ideal tool to explore the potential of CD24 as an oncogene and a target for immunotherapy in vitro and in vivo. J Biol Chem 286: 40548–40555. pmid:21976680
- 17. Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, et al. (2006) CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 131: 630–639. pmid:16890615
- 18. Wang W, Wang X, Peng L, Deng Q, Liang Y, et al. CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci 101: 112–119. pmid:19860845
- 19. Jacobi J, Tam BY, Sundram U, von Degenfeld G, Blau HM, et al. (2004) Discordant effects of a soluble VEGF receptor on wound healing and angiogenesis. Gene Ther 11: 302–309. pmid:14737090
- 20. Maffulli N, Longo UG, Franceschi F, Rabitti C, Denaro V (2008) Movin and Bonar scores assess the same characteristics of tendon histology. Clin Orthop Relat Res 466: 1605–1611. pmid:18437501
- 21. Bretz N, Noske A, Keller S, Erbe-Hofmann N, Schlange T, et al. CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor–2 (TFPI–2) in a c-Src-dependent fashion. Clin Exp Metastasis 29: 27–38. pmid:21984372
- 22. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, et al. (2005) CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65: 10783–10793. pmid:16322224
- 23. Lim SC, Oh SH (2005) The role of CD24 in various human epithelial neoplasias. Pathol Res Pract 201: 479–486. pmid:16164042
- 24. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70. pmid:10647931
- 25. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, et al. (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene 24: 3397–3408. pmid:15735721
- 26. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650–1659. pmid:3537791
- 27. Naumov I, Zilberberg A, Shapira S, Avivi D, Kazanov D, et al. (2014) CD24 knockout prevents colorectal cancer in chemically induced colon carcinogenesis and in APC(Min)/CD24 double knockout transgenic mice. Int J Cancer 135: 1048–1059. pmid:24500912
- 28. Shapira S, Kazanov D, Weisblatt S, Starr A, Arber N, et al. (2011) The CD24 protein inducible expression system is an ideal tool to explore the potential of CD24 as an oncogene and a target for immunotherapy in vitro and in vivo. J Biol Chem 286: 40548–40555. pmid:21976680